Skip to main content

Table 3 Base-case analysis

From: Health economic evaluation of Human Papillomavirus vaccines in women from Venezuela by a lifetime Markov cohort model

  Results Differences (Gains)
  No vaccination (NV) Quadrivalent (QV) Bivalent (BV) QV - NV BV - NV BV-QV
A: Health outcomes and disease-related costs
Undiscounted
 LYs 18,351,285 18,395,244 18,398,735 43,959 47,451 3,491
 QALYs 18,337,584 18,390,430 18,393,973 52,845 56,389 3,544
 Cervical cancer cases 7,398 2,967 2,616 −4,431 −4,781 −350
 Cervical cancer deaths 3,701 1,558 1,391 −2,143 −2,310 −168
 Genital Warts (new and recurrent) 21,025 2,566 21,025 −18,459 0 18,459
 Total cost other than vaccinationa 11,295.9 VEF 7,109.9 VEF 7,107.3 VEF −4,186.0 VEF −4,188.6 VEF −2.6 VEF
  Costs of screening 4,323.0 VEF 4,396.1 VEF 4,383.3 VEF 73.1 VEF 60.3 VEF −12.8 VEF
  Costs of CIN 1 601.4 VEF 303.3 VEF 344.9 VEF −298.1 VEF −256.5 VEF 41.5 VEF
  Costs of CIN 2/3 262.3 VEF 122.7 VEF 102.6 VEF −139.6 VEF −159.7 VEF −20.1 VEF
  Costs of warts 309.2 VEF 37.7 VEF 309.3 VEF −271.4 VEF 0.1 VEF 271.6 VEF
  Costs of cancer 5,800.1 VEF 2,250.1 VEF 1,967.3 VEF −3,550.0 VEF −3,832.7 VEF −282.7 VEF
 Discounted (5%)
 LYs 5,277,952 5,281,034 5,281,282 3,082 3,330 248
 QALYs 5,276,066 5,280,461 5,280,552 4,395 4,486 91
 Total cost other than vaccinationa 2,435.2 VEF 1,602.7 VEF 1,672.5 VEF −832.6 VEF −762.8 VEF 69.8 VEF
  Costs of screening 1,130.3 VEF 1,151.9 VEF 1,148.5 VEF 21.6 VEF 18.2 VEF −3.5 VEF
  Costs of CIN 1 167.1 VEF 82.8 VEF 91.8 VEF −84.3 VEF −75.4 VEF 9.0 VEF
  Costs of CIN 2/3 79.5 VEF 35.2 VEF 28.6 VEF −44.3 VEF −50.9 VEF −6.6 VEF
  Costs of warts 136.7 VEF 16.7 VEF 136.7 VEF −120.0 VEF 0.0 VEF 120.0 VEF
  Costs of cancer 921.6 VEF 316.0 VEF 266.9 VEF −605.6 VEF −654.7 VEF −49.1 VEF
B: Vaccine costs per scenarioa       
 2: Both vaccines = 8.5 US$; 2-dose scheme - FX 6.3 0 VEF 26.9 VEF 26.9 VEF 26.9 VEF 26.9 VEF 0 VEF
 4: Both vaccines = 8.5 US$; 2-dose scheme - FX: 170 0 VEF 726.2 VEF 726.2 VEF 726.2 VEF 726.2 VEF 0 VEF
 6: BV: 8.5 US$ QV: 13.79 US$; 2-dose scheme - FX 6.3 0 VEF 43.7 VEF 26.9 VEF 43.7 VEF 26.9 VEF −16.7 VEF
 8: BV: 8.5 US$ QV: 13.79 US$; 2-dose scheme - FX: 170 0 VEF 1,178.1 VEF 726.2 VEF 1,178.1 VEF 726.2 VEF −451.9 VEF
  1. Notes: A. Health outcomes and disease related costs (with and without discounting); B. Cost of vaccination (Scenarios 2, 4, 6 and 8)
  2. Abbreviations: NV no vaccination, QV quadrivalent, BV bivalent, FX foreign exchange rate (VEF per US$), CC cervical cancer. (See scenarios 1, 3, 5, 7 in Additional file 1: Table S2), VEF Venezuelan bolívar fuerte, QALYs quality-adjusted life years, LYs life-years, CIN cervical intraepithelial neoplasia, US$ United States dollar
  3. aCosts are expressed in millions of VEF, 2015